China Surges at 12.4% CAGR on Government-Backed Precision Medicine and Genomics Investment
DNA Diagnostics Market size was valued at USD 14.07 billion in 2025 and is projected to grow from USD 15.38 billion in 2026 to USD 31.38 billion by 2034, registering a CAGR of 9.32%, according to Polaris Market Research. DNA diagnostics use a person’s genetic material to detect mutations linked to hereditary illnesses, infections, cancers and drug response, supporting early diagnosis and accurate analysis of a patient’s condition. Rising prevalence of genetic disorders and cancers and the global shift toward precision medicine are the key growth factors.
How testing works
Testing typically starts with a blood, saliva, tissue or cheek-cell sample from which DNA is isolated and analyzed with methods such as PCR or next-generation sequencing (NGS). Experts then interpret results against genetic databases. Compared with traditional diagnostics, DNA testing works at the molecular level, can detect disease before symptoms appear and can predict inherited risk, enabling targeted treatment rather than standard protocols.
What is driving demand
Expanding testing services are broadening access to the DNA Diagnostics Market. Clinical and direct-to-consumer options, including at-home saliva or cheek-swab kits that report on ancestry, carrier status and some health issues, are bringing genetic information to more people. In March 2026, Co-Diagnostics extended commercialization of its PCR Pro and SARAGENE PCR DNA diagnostic products into South Asia. Investment is also strong, with the Polaris page citing Function Health’s USD 298 million Series B and Beeline Medicines’ USD 300 million Series A as examples of funding in multi-analyte biomarker monitoring.
Personalized medicine and rare disease detection add momentum. Physicians use a patient’s genotype to tailor therapy and anticipate drug response, especially in oncology, rare conditions and pharmacogenomics. PCR and NGS can identify mutations that routine lab tests miss, shortening the diagnostic journey for rare inherited diseases. AI further helps by analyzing genetic data to detect disease-associated mutations faster and spot complex patterns that traditional techniques may overlook.
Segment leaders and fast movers
Cancer genetics tests held the largest application share at 31.6% in 2025, reflecting rising cancer prevalence and growing adoption of precision oncology. The National Cancer Institute reported nearly 20 million new cancer cases and 9.7 million cancer deaths globally in 2022. Reagents and kits are projected to grow at an 11.2% CAGR as comprehensive testing kits and consumables demand rise. In July 2025, Creative Diagnostics introduced Host Cell DNA Assay Kits for detecting residual host cell DNA, and in February 2026 New England Biolabs released its Monarch Mag cell-free DNA extraction kit for scalable cfDNA isolation.
Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/dna-diagnostics-market
Regional outlook
Asia Pacific led with a 38.7% revenue share in 2025 on advances in genomics and proteomics, expanding molecular diagnostics capacity and rising healthcare investment. North America is expected to grow at a 10.8% CAGR, supported by established biotechnology firms, strong research funding and wide adoption of genetic testing. China is projected to grow at 12.4% on healthcare infrastructure investment and government support for precision medicine. In May 2024, SOPHiA GENETICS collaborated with Microsoft and NVIDIA on a scalable whole genome sequencing analysis solution for healthcare facilities.
Challenges and opportunities
High costs of advanced equipment remain the main challenge. Opportunities are building around non-invasive liquid biopsies and minimal residual disease (MRD) testing, while growing use of companion diagnostics and home genetic tests opens further avenues.
Competitive landscape and deals
Leading companies include Abbott, Agilent Technologies, Avalon GloboCare, Beckman Coulter, Bio-Rad Laboratories, Cepheid, Roche, GE HealthCare, Hologic, Illumina, QIAGEN, Siemens Healthcare and Thermo Fisher Scientific. In March 2026, Abbott completed its acquisition of Exact Sciences to strengthen its position in cancer screening and diagnostics. In April 2024, Bio-Rad introduced the ddPLEX ESR1 Mutation Detection Kit, an ultrasensitive multiplexed digital PCR assay for oncology. Thermo Fisher’s TaqPath PCR kits for infections such as tuberculosis, hepatitis B and C, and HIV, along with an HLA-B27 genetic analysis kit, received licensing rights from India’s CDSCO in February 2023.
DNA Diagnostics Market growth through 2034 will be shaped by faster PCR and NGS workflows, AI-assisted interpretation and wider access through at-home and clinical channels. Cancer testing, reagents and kits, and Asia Pacific and China are set to anchor demand, while liquid biopsy and MRD testing open the next growth frontier. Companies that pair accurate molecular assays with scalable services and software are best positioned to capture it.
More Trending Latest Reports By Polaris Market Research:
Targeted DNA RNA Sequencing Market
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Jogos
- Gardening
- Health
- Início
- Literature
- Music
- Networking
- Outro
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness